Drug Trial News

RSS

Broad-spectrum influenza vaccine candidate shows safety, immunogenicity data across three dose levels

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that The Lancet Infectious Diseases published results from the company's OVX836-003 study under the title, "Immunogenicity, safety and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: randomized, double-blind placebo-controlled, Phase 2a trial."

27 Jul 2023

Exclusion of chronic kidney disease patients from cardiovascular trials leaves significant evidence gaps

Study looks at how and where patients with CKD have been excluded from CVD RCTs over the last two decades.

24 Jul 2023

ECOG-ACRIN launches new trial to evaluate nilotinib and paclitaxel for advanced cancers

The ECOG-ACRIN Cancer Research Group has enrolled the first patient in a new treatment trial to evaluate the effectiveness of adding nilotinib to standard paclitaxel chemotherapy.

20 Jul 2023

New brain-penetrant agonist shows promise in protecting dopamine neurons for Parkinson's disease treatment

Researchers reported on Nurr1 as a promising therapeutic target for managing Parkinson's disease (PD).

20 Jul 2023

Donanemab: A trailblazer for Alzheimer's disease treatment?

A recent study evaluated the efficacy and side effects of donanemab, an antibody that could possibly clear brain amyloid plaque in early symptomatic Alzheimer disease (AD).

20 Jul 2023

Donanemab may offer new hope for people with early Alzheimer's disease

The data reported today by Eli Lilly from the TRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer's disease demonstrate an important advancement in Alzheimer's research and treatment.

17 Jul 2023

PALACE study: Direct oral challenge can safely remove penicillin allergy label

Penicillin allergy affects more than 25 million people in the United States (up to 1 in 10 Americans) and has been shown to lead to particularly poor health outcomes in pregnant women and surgical patients. It is also a public health threat, leading to antibiotic resistance and infections in hospitalized patients that can be life threatening.

17 Jul 2023

Donanemab shows promise in slowing Alzheimer's disease

With yet a third new Alzheimer's drug expected to be approved by the Food and Drug Administration (FDA), the field is beginning to show progress in the fight to slow the disease.

17 Jul 2023

Exploring the efficacy of topical lidocaine in individuals with chronic neck pain

A team of researchers investigated the efficacy of lidocaine for the treatment of neck pain.

17 Jul 2023

NIH funding for phased clinical trials represents <3.5% of total spending

The U.S. National Institutes of Health (NIH) contributed $8.1 billion in project funding for phased clinical trials involving drugs approved by the FDA from 2010-2019, according to a new study from Bentley University's Center for Integration of Science and Industry.

14 Jul 2023

Pembrolizumab combination therapies effective for advanced NSCLC, study shows

While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in the tumor microenvironment.

12 Jul 2023

Cytisinicline could offer adult cigarette smokers a potential new treatment option

The first large-scale U.S. clinical trial of cytisinicline, led by a Massachusetts General Hospital (MGH) investigator, found the smoking cessation medication to be effective and well tolerated in adults who wished to break their nicotine dependence.

11 Jul 2023

New clinical trial seeks a regenerative pharmaceutical solution for meniscal tears

With support from Amplicore, a University of Cincinnati spinoff biopharmaceutical company, researchers at UC have begun a Department of Defense-funded clinical trial that seeks a regenerative pharmaceutical solution for meniscal tears.

10 Jul 2023

Two anti-inflammatory drugs reduce deaths in severe COVID-19 patients

Two anti-inflammatory drugs, abatacept and infliximab, reduced deaths among patients hospitalized with severe COVID-19, according to a national study led by Washington University School of Medicine in St. Louis. William G. Powderly, MD, (right) who led the large clinical trial, discusses patient conditions with Maanasi Samant, MD, in the intensive care unit at Barnes-Jewish Hospital, one of the major trial sites, during the COVID-19 pandemic.

10 Jul 2023

Clinical trial of three-month TB treatment regimen closed due to high rate of unfavorable outcomes

Previous
1
...
36
37
38
39
40
41
42
...
1162
Next

Drug Trial News

Broad-spectrum influenza vaccine candidate shows safety, immunogenicity data across three dose levels

Exclusion of chronic kidney disease patients from cardiovascular trials leaves significant evidence gaps

ECOG-ACRIN launches new trial to evaluate nilotinib and paclitaxel for advanced cancers

New brain-penetrant agonist shows promise in protecting dopamine neurons for Parkinson's disease treatment

Donanemab: A trailblazer for Alzheimer's disease treatment?

Donanemab may offer new hope for people with early Alzheimer's disease

PALACE study: Direct oral challenge can safely remove penicillin allergy label

Donanemab shows promise in slowing Alzheimer's disease

Exploring the efficacy of topical lidocaine in individuals with chronic neck pain

NIH funding for phased clinical trials represents <3.5% of total spending

Pembrolizumab combination therapies effective for advanced NSCLC, study shows

Cytisinicline could offer adult cigarette smokers a potential new treatment option

New clinical trial seeks a regenerative pharmaceutical solution for meniscal tears

Two anti-inflammatory drugs reduce deaths in severe COVID-19 patients

Clinical trial of three-month TB treatment regimen closed due to high rate of unfavorable outcomes

SYS6006 investigational COVID-19 mRNA vaccine shows promise as fourth dose booster

PSI-developed drug could increase survival chances for metastatic prostate cancer patients

Growth factor study reveals potential breakthrough in obesity management

Tirzepatide triumphs in significant weight reduction for people with type 2 diabetes

The Lancet study unveils exciting findings on retatrutide as a novel treatment for type 2 diabetes

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News